C
Cuu Long Pharmaceutical JSC
VN:DCL
Cuu Long Pharmaceutical JSC
VN:DCL
Price:
57 400
VND
-0.52%
Market Closed
Market Cap:
₫4.2T
Income Statement
Earnings Waterfall
Cuu Long Pharmaceutical JSC
Cuu Long Pharmaceutical JSC
Income Statement
Cuu Long Pharmaceutical JSC
Cuu Long Pharmaceutical JSC
Currency: VND
| Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||
| Interest Expense |
36 476
|
34 313
|
31 824
|
37 685
|
36 283
|
34 572
|
33 921
|
31 749
|
29 170
|
28 602
|
19 695
|
25 387
|
0
|
0
|
|
| Revenue |
703 634
N/A
|
750 434
+7%
|
770 611
+3%
|
865 501
+12%
|
1 015 686
+17%
|
1 035 081
+2%
|
1 084 926
+5%
|
1 099 859
+1%
|
1 143 946
+4%
|
1 185 106
+4%
|
902 614
-24%
|
1 306 797
+45%
|
1 085 895
-17%
|
1 409 133
+30%
|
|
| Gross Profit | |||||||||||||||
| Cost of Revenue |
(493 482)
|
(532 225)
|
(545 361)
|
(613 568)
|
(733 585)
|
(756 290)
|
(828 056)
|
(878 397)
|
(934 032)
|
(962 855)
|
(722 227)
|
(1 102 093)
|
(904 284)
|
(1 192 560)
|
|
| Gross Profit |
210 152
N/A
|
218 210
+4%
|
225 249
+3%
|
251 933
+12%
|
282 100
+12%
|
278 791
-1%
|
256 870
-8%
|
221 462
-14%
|
209 914
-5%
|
222 250
+6%
|
180 387
-19%
|
204 704
+13%
|
181 611
-11%
|
216 573
+19%
|
|
| Operating Income | |||||||||||||||
| Operating Expenses |
(123 372)
|
(126 795)
|
(134 373)
|
(142 725)
|
(153 815)
|
(152 843)
|
(137 195)
|
(135 573)
|
(139 188)
|
(127 901)
|
(106 535)
|
(144 874)
|
(116 629)
|
(148 135)
|
|
| Selling, General & Administrative |
(116 110)
|
(115 957)
|
(124 821)
|
(134 816)
|
(148 686)
|
(149 202)
|
(134 376)
|
(131 521)
|
(136 112)
|
(130 421)
|
(109 068)
|
(140 178)
|
(111 681)
|
(141 554)
|
|
| Depreciation & Amortization |
(3 355)
|
(3 506)
|
(3 714)
|
(3 712)
|
(3 725)
|
(3 772)
|
(3 952)
|
(4 195)
|
(4 364)
|
(4 505)
|
(3 402)
|
(4 607)
|
(3 702)
|
(5 169)
|
|
| Other Operating Expenses |
(3 907)
|
(7 333)
|
(5 837)
|
(4 197)
|
(1 405)
|
132
|
1 133
|
143
|
1 288
|
7 024
|
5 935
|
(89)
|
(1 246)
|
(1 413)
|
|
| Operating Income |
86 781
N/A
|
91 414
+5%
|
90 876
-1%
|
109 208
+20%
|
128 285
+17%
|
125 947
-2%
|
119 675
-5%
|
85 889
-28%
|
70 726
-18%
|
94 349
+33%
|
73 852
-22%
|
59 830
-19%
|
64 982
+9%
|
68 438
+5%
|
|
| Pre-Tax Income | |||||||||||||||
| Interest Income Expense |
23 107
|
20 626
|
12 646
|
10 176
|
13 162
|
16 382
|
11 939
|
9 760
|
6 432
|
16
|
(207)
|
8 937
|
1 938
|
(3 493)
|
|
| Gain/Loss on Disposition of Assets |
0
|
17
|
0
|
0
|
0
|
0
|
0
|
371
|
0
|
371
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
396
|
(145)
|
195
|
169
|
94
|
971
|
1 095
|
622
|
953
|
(7 074)
|
(6 998)
|
10
|
(6 300)
|
(5 987)
|
|
| Pre-Tax Income |
110 284
N/A
|
111 912
+1%
|
103 717
-7%
|
119 554
+15%
|
141 542
+18%
|
143 301
+1%
|
132 709
-7%
|
96 643
-27%
|
78 111
-19%
|
87 662
+12%
|
66 646
-24%
|
68 777
+3%
|
60 620
-12%
|
58 958
-3%
|
|
| Net Income | |||||||||||||||
| Tax Provision |
(22 528)
|
(22 730)
|
(21 167)
|
(24 367)
|
(28 628)
|
(29 174)
|
(26 809)
|
(19 614)
|
(15 976)
|
(17 917)
|
(13 858)
|
(14 631)
|
(14 829)
|
(16 232)
|
|
| Income from Continuing Operations |
87 756
|
89 182
|
82 550
|
95 187
|
112 914
|
114 127
|
105 901
|
77 029
|
62 134
|
69 744
|
52 788
|
54 145
|
45 792
|
42 726
|
|
| Income to Minority Interest |
(1 796)
|
(1 778)
|
(1 700)
|
(1 570)
|
(1 273)
|
(884)
|
(606)
|
(442)
|
(417)
|
(475)
|
(389)
|
(574)
|
(440)
|
(591)
|
|
| Net Income (Common) |
85 961
N/A
|
87 405
+2%
|
80 850
-7%
|
93 616
+16%
|
111 641
+19%
|
113 243
+1%
|
105 295
-7%
|
76 588
-27%
|
59 717
-22%
|
69 269
+16%
|
52 399
-24%
|
53 571
+2%
|
46 352
-13%
|
43 135
-7%
|
|
| EPS (Diluted) |
1 508.08
N/A
|
1 424.48
-6%
|
1 106.9
-22%
|
1 353.87
+22%
|
1 591.22
+18%
|
1 550.4
-3%
|
1 716.05
+11%
|
1 064.57
-38%
|
817.59
-23%
|
948.35
+16%
|
717.39
-24%
|
733.44
+2%
|
634.6
-13%
|
590.56
-7%
|
|
Switch to:
Switch to:
See Also
Discover More
